|
Post by mnkdfann on Jun 13, 2016 12:14:29 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 13, 2016 12:15:47 GMT -5
Honestly who gives a shit. I did nothing to the stock price.....lol
Sales, sales, sales, sales........
|
|
|
PPS
Jun 13, 2016 13:47:49 GMT -5
Post by agedhippie on Jun 13, 2016 13:47:49 GMT -5
That's because it's no big deal. The JDRF will partner with anyone in the diabetes field. You are wrong about JDRF. Their biggest push is the artificial pancreas using Afrezza during mealtime. The director of JDRF IS T1 and he uses Afrezza. The number 1 focus for JDRF has and always will be a cure, not a treatment. Their biggest push is definitely not the artificial pancreas + Afrezza. If it was it wouldn't be 3 years since the last experiment concluded. Even the AP is only one of their focus areas. It's good to be involved with JDRF but don't overestimate either our importance to JDRF, or the significance.
|
|
|
Post by hillsave on Jun 13, 2016 13:53:35 GMT -5
You are wrong about JDRF. Their biggest push is the artificial pancreas using Afrezza during mealtime. The director of JDRF IS T1 and he uses Afrezza. The number 1 focus for JDRF has and always will be a cure, not a treatment. Their biggest push is definitely not the artificial pancreas + Afrezza. If it was it wouldn't be 3 years since the last experiment concluded. Even the AP is only one of their focus areas. It's good to be involved with JDRF but don't overestimate either our importance to JDRF, or the significance. I agree with your statement about a cure for T1. My son has T1 for 14 years and his mother trains fund raisers all over the country how to do a better job raising $$. JDRF has many important research projects underway. Including a closed loop system that will put the control of BG levels in the hands of a micro chip. The AP is just one of the projects. Sorry for the misquote.
|
|
Deleted
Deleted Member
Posts: 0
|
PPS
Jul 19, 2016 0:28:07 GMT -5
cm5 likes this
Post by Deleted on Jul 19, 2016 0:28:07 GMT -5
You're right, it's not a big deal at all. In fact, neither is this: —The JDRF Glucose Control Program supports the development of novel insulin formulations and drugs that can be used in conjunction with insulin therapy to provide better control of blood-sugar levels. In summer 2014, JDRF industry partner MannKind received FDA approval for Afrezza, a rapid-acting inhaled insulin that can be used at the beginning of meals to more tightly control the rise in blood-sugar levels that occur after eating. ■ A JDRF-supported study published in the Journal of Diabetes Science and Technology’s May 2015 issue showed that use of Afrezza as a mealtime bolus in conjunction with an experimental AP system significantly increased the percentage of time that people using the system stayed in ideal blood-glucose range. Source: www.kydiabetes.net/images/files/JDRF%2015%20Top%20Research%20Advances.pdfThis isn't a big deal either: —Prevention in the Hands of Future Generations JDRF is funding the Fr1da project, in which 3-and 4-year-olds in Bavaria, Germany, are screened for early-stage markers of T1D at well-child visits. Those who test positive for the markers can enroll in a study monitoring disease progression or a trial testing whether oral insulin can stop progression of T1D. This trial raises the exciting prospect of stopping T1D in its tracks and changing the future for those at risk of developing T1D. Source: jdrf.org/blog/2016/05/20/jdrf-top-advances/You're right, the fact that MannKind has an inhaled insulin, and is entering into a pediatric study with JDRF is definitely not a big deal. And exactly which of those moved the price and by how much? I hate to keep hammering this point but JDRF works with anyone in the diabetes space - there is nothing special about this and the market knows that. — According to your opinion, MannKind should have partnered with them years ago then. — Why did MannKind just now officially partner with the JDRF this year then? — Nothing special" you say? — Well, it is a research foundation that invested 92 million functional dollars into their research in 2015. — I'm trying to understand your assertment that it is no big deal as I look at these companies partnered with them: Lilly, Novo Nordisk, Roche, Medtronic, Sanofi, Dexcom, Abbott, and Genentech. Looks like just anyone to me too.
|
|
|
PPS
Jul 19, 2016 8:45:03 GMT -5
Post by agedhippie on Jul 19, 2016 8:45:03 GMT -5
And exactly which of those moved the price and by how much? I hate to keep hammering this point but JDRF works with anyone in the diabetes space - there is nothing special about this and the market knows that. — According to your opinion, MannKind should have partnered with them years ago then. — Why did MannKind just now officially partner with the JDRF this year then? — Nothing special" you say? — Well, it is a research foundation that invested 92 million functional dollars into their research in 2015. — I'm trying to understand your assertment that it is no big deal as I look at these companies partnered with them: Lilly, Novo Nordisk, Roche, Medtronic, Sanofi, Dexcom, Abbott, and Genentech. Looks like just anyone to me too. To answer your questions - — According to your opinion, MannKind should have partnered with them years ago then. They were already partners. — Why did MannKind just now officially partner with the JDRF this year then? Mannkind have been a partner for years. — Nothing special" you say? — Well, it is a research foundation that invested 92 million functional dollars into their research in 2015. Yes, and they pass that money out to research institutes. The names you mention each give JDRF several million dollars a year. In exchange they get a nice high profile with JDRF and hence amongst their target market. — I'm trying to understand your assertment that it is no big deal as I look at these companies partnered with them: Lilly, Novo Nordisk, Roche, Medtronic, Sanofi, Dexcom, Abbott, and Genentech. Looks like just anyone to me too. Why do they do it? Publicity, marketing, and logistics for trials.
|
|
Deleted
Deleted Member
Posts: 0
|
PPS
Jul 19, 2016 13:47:43 GMT -5
Post by Deleted on Jul 19, 2016 13:47:43 GMT -5
— According to your opinion, MannKind should have partnered with them years ago then. — Why did MannKind just now officially partner with the JDRF this year then? — Nothing special" you say? — Well, it is a research foundation that invested 92 million functional dollars into their research in 2015. — I'm trying to understand your assertment that it is no big deal as I look at these companies partnered with them: Lilly, Novo Nordisk, Roche, Medtronic, Sanofi, Dexcom, Abbott, and Genentech. Looks like just anyone to me too. To answer your questions - — According to your opinion, MannKind should have partnered with them years ago then. They were already partners. — Why did MannKind just now officially partner with the JDRF this year then? Mannkind have been a partner for years. — Nothing special" you say? — Well, it is a research foundation that invested 92 million functional dollars into their research in 2015. Yes, and they pass that money out to research institutes. The names you mention each give JDRF several million dollars a year. In exchange they get a nice high profile with JDRF and hence amongst their target market. — I'm trying to understand your assertment that it is no big deal as I look at these companies partnered with them: Lilly, Novo Nordisk, Roche, Medtronic, Sanofi, Dexcom, Abbott, and Genentech. Looks like just anyone to me too. Why do they do it? Publicity, marketing, and logistics for trials. • They were already partners. — Source? They were never partners. MannKind's own press release from 2010 never states they entered into a partnership with JDRF. They simply provided Afrezza for the artifical pancreas research. They did, however, announce this year that they entered into a partnership with JDRF. • Mannkind have been a partner for years. — Source? • Yes, and they pass that money out to research institutes. — "The collaboration will combine JDRF's significant scientific and human resources with MannKind's active participation in the field of diabetes research and development in order to advance new treatments and therapies in areas of strategic alignment that can transform the lives of people with diabetes. A focus of the collaboration will be on the use of Afrezza®, with its unique insulin delivery method, in the pediatric population." — JDRF will be funding this. • Why do they do it? Publicity, marketing, and logistics for trials. — But you have said time and time again that the JDRF is nothing important and will partner with anyone. Why would they waste their time and money with them then?
|
|
|
PPS
Jul 19, 2016 14:52:55 GMT -5
Post by agedhippie on Jul 19, 2016 14:52:55 GMT -5
• Why do they do it? Publicity, marketing, and logistics for trials. — But you have said time and time again that the JDRF is nothing important and will partner with anyone. Why would they waste their time and money with them then? Publicity, marketing, and logistics for trials.
|
|
Deleted
Deleted Member
Posts: 0
|
PPS
Jul 19, 2016 17:58:02 GMT -5
via mobile
Post by Deleted on Jul 19, 2016 17:58:02 GMT -5
With short interest increased and pps declining I am guessing some one got news that there is no Sanofi parting check and management failed again... With Pascale let go, new management would be tough to negotiate?
|
|
|
PPS
Jul 20, 2016 8:17:47 GMT -5
via mobile
Post by beardawg on Jul 20, 2016 8:17:47 GMT -5
• Why do they do it? Publicity, marketing, and logistics for trials. — But you have said time and time again that the JDRF is nothing important and will partner with anyone. Why would they waste their time and money with them then? Publicity, marketing, and logistics for trials. I think salsa was making the point that if JDRF is really not that important and will partner with anyone, how could MNKD be getting publicity and marketing from them - everyone else does it so it doesn't distinguish them or amount to any groundbreaking event. "Ho hum" news isn't publicity. About the only thing they could benefit from, when taking all of your comments together, is trial logistics, which wouldn't be worth it to spend the time pursuing it.
|
|
|
PPS
Jul 20, 2016 8:21:20 GMT -5
Post by kbrion77 on Jul 20, 2016 8:21:20 GMT -5
Publicity, marketing, and logistics for trials. I think salsa was making the point that if JDRF is really not that important and will partner with anyone, how could MNKD be getting publicity and marketing from them - everyone else does it so it doesn't distinguish them or amount to any groundbreaking event. "Ho hum" news isn't publicity. About the only thing they could benefit from, when taking all of your comments together, is trial logistics, which wouldn't be worth it to spend the time pursuing it. If Pfeffer eats a cheeseburger for lunch it is news around here.
|
|
Deleted
Deleted Member
Posts: 0
|
PPS
Jul 20, 2016 8:32:27 GMT -5
Post by Deleted on Jul 20, 2016 8:32:27 GMT -5
With short interest increased and pps declining I am guessing some one got news that there is no Sanofi parting check and management failed again... With Pascale let go, new management would be tough to negotiate? I never understood the logic behind a settlement payment. I think if anything Matt was trying to keep the share price propped up for the much needed dilution they would eventually do. If MNKD goes under then most of the money they owe SNY is lost. Why would SNY give them more money now? SNY could just wait this out the next 6-9 months. MNKD has no leverage right now with SNY.
|
|
|
Post by mnkdorbust on Jul 20, 2016 8:39:28 GMT -5
With short interest increased and pps declining I am guessing some one got news that there is no Sanofi parting check and management failed again... With Pascale let go, new management would be tough to negotiate? I never understood the logic behind a settlement payment. I think if anything Matt was trying to keep the share price propped up for the much needed dilution they would eventually do. If MNKD goes under then most of the money they owe SNY is lost. Why would SNY give them more money now? SNY could just wait this out the next 6-9 months. MNKD has no leverage right now with SNY. Just like everything else I feel everything is hinged on scripts. If the new sales force can go out and get numbers even 2x that of the "SNY Attempt" then wouldn't they have more (or at least some) leverage for a potential settlement? I would think it would rightly show that SNY sandbagged it.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 20, 2016 11:25:21 GMT -5
I never understood the logic behind a settlement payment. I think if anything Matt was trying to keep the share price propped up for the much needed dilution they would eventually do. If MNKD goes under then most of the money they owe SNY is lost. Why would SNY give them more money now? SNY could just wait this out the next 6-9 months. MNKD has no leverage right now with SNY. Just like everything else I feel everything is hinged on scripts. If the new sales force can go out and get numbers even 2x that of the "SNY Attempt" then wouldn't they have more (or at least some) leverage for a potential settlement? I would think it would rightly show that SNY sandbagged it. I agree a 100% about scripts. Its frustrating to read so many posters who are just out of touch with the fact that MNKD is a drug company and they need to sell their product. They need to sell Afrezza. As investors we should not be concerned about RLS milestone (cause we dont even know anything about the company) SNY settlement or international partners. They need to prove Afrezza can sell, anything else is just gravy at this point.
|
|
Deleted
Deleted Member
Posts: 0
|
PPS
Jul 20, 2016 14:08:44 GMT -5
Post by Deleted on Jul 20, 2016 14:08:44 GMT -5
Just like everything else I feel everything is hinged on scripts. If the new sales force can go out and get numbers even 2x that of the "SNY Attempt" then wouldn't they have more (or at least some) leverage for a potential settlement? I would think it would rightly show that SNY sandbagged it. I agree a 100% about scripts. Its frustrating to read so many posters who are just out of touch with the fact that MNKD is a drug company and they need to sell their product. They need to sell Afrezza. As investors we should not be concerned about RLS milestone (cause we dont even know anything about the company) SNY settlement or international partners. They need to prove Afrezza can sell, anything else is just gravy at this point.
I agree, above all else, MannKind's future heavily depends on Afrezza. However, we should be concerned about milestone payments from RLS because MannKind is currently not making a profit, and the commercialization efforts for Afrezza cost money. If RLS ends up being ground-breaking and successful, then MannKind will gain more attention and recognition, which could greatly help in the commercialization of Afrezza. I think at this point RLS is the only thing that is outside of Mannkind that could potentially catapult MannKind into public awareness—if of course, their new drug(s) end up being as ground-breaking as Andrea Leone-Bay advertises them to be.
|
|